Economics of ramucirumab for metastatic colorectal cancer.

about

Economics of ramucirumab for metastatic colorectal cancer.

Item

http://www.wikidata.org/entity/Q39003764

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Economics of ramucirumab for metastatic colorectal cancer.

@en

Economics of ramucirumab for metastatic colorectal cancer.

@nl

type

Item

label

Economics of ramucirumab for metastatic colorectal cancer.

@en

Economics of ramucirumab for metastatic colorectal cancer.

@nl

prefLabel

Economics of ramucirumab for metastatic colorectal cancer.

@en

Economics of ramucirumab for metastatic colorectal cancer.

@nl

P1476

Economics of ramucirumab for metastatic colorectal cancer.

@en

P2093

Christine G Kohn

http://www.w3.org/2001/XMLSchema#string

Daniel A Goldstein

http://www.w3.org/2001/XMLSchema#string

Simon B Zeichner

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2015

Development of biosimilars in an era of oncologic drug shortages

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data.

Practical approach for using Medicare data to estimate costs for cost-effectiveness analysis.

Does Medicare have an implicit cost-effectiveness threshold?

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, doubl

P304

733-745

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737167.2016.1259070

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27828732

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer